Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma.

Drug development Macroautophagy Myeloma

Journal

Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035

Informations de publication

Date de publication:
2019
Historique:
received: 04 03 2019
revised: 09 04 2019
accepted: 23 04 2019
entrez: 25 5 2019
pubmed: 28 5 2019
medline: 28 5 2019
Statut: epublish

Résumé

Multiple myeloma (MM) is a tumor of plasma cells (PCs). Due to the intense immunoglobulin secretion, PCs are prone to endoplasmic reticulum stress and activate several stress-managing pathways, including autophagy. Indeed, autophagy deregulation is maladaptive for MM cells, resulting in cell death. CK1α, a pro-survival kinase in MM, has recently been involved as a regulator of the autophagic flux and of the transcriptional competence of the autophagy-related transcription factor FOXO3a in several cancers. In this study, we investigated the role of CK1α in autophagy in MM. To study the autophagic flux we generated clones of MM cell lines expressing the mCherry-eGFP-LC3B fusion protein. We observed that CK1 inhibition with the chemical ATP-competitive CK1 α/δ inhibitor D4476 resulted in an impaired autophagic flux, likely due to an alteration of lysosomes acidification. However, D4476 caused the accumulation of the transcription factor FOXO3a in the nucleus, and this was paralleled by the upregulation of mRNA coding for autophagic genes. Surprisingly, silencing of CK1α by RNA interference triggered the autophagic flux. However, FOXO3a did not shuttle into the nucleus and the transcription of autophagy-related FOXO3a-dependent genes was not observed. Thus, while the chemical inhibition with the dual CK1α/δ inhibitor D4476 induced cell death as a consequence of an accumulation of ineffective autophagic vesicles, on the opposite, CK1α silencing, although it also determined apoptosis, triggered a full activation of the early autophagic flux, which was then not supported by the upregulation of autophagic genes. Taken together, our results indicate that the family of CK1 kinases may profoundly influence MM cells survival also through the modulation of the autophagic pathway.

Identifiants

pubmed: 31123604
doi: 10.1038/s41420-019-0179-1
pii: 179
pmc: PMC6529432
doi:

Types de publication

Journal Article

Langues

eng

Pagination

98

Déclaration de conflit d'intérêts

Conflict of interestThe authors declare that they have no conflict of interest.

Références

Oncogene. 1999 Nov 22;18(49):6853-66
pubmed: 10602461
EMBO J. 2000 Nov 1;19(21):5720-8
pubmed: 11060023
EMBO Rep. 2004 Jan;5(1):60-5
pubmed: 14710188
Cell Mol Life Sci. 2004 Jun;61(12):1439-54
pubmed: 15197469
Cell Signal. 2005 Jun;17(6):675-89
pubmed: 15722192
Nature. 2009 Mar 5;458(7234):92-6
pubmed: 19118383
Blood. 2009 May 28;113(22):5412-7
pubmed: 19179464
Mol Cancer Ther. 2009 Jul;8(7):1974-84
pubmed: 19509276
Cell. 2010 Feb 5;140(3):313-26
pubmed: 20144757
J Pathol. 2010 May;221(1):3-12
pubmed: 20225336
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18511-6
pubmed: 20937856
Annu Rev Pathol. 2011;6:249-74
pubmed: 21261519
Mol Biol Cell. 2011 Apr 15;22(8):1321-9
pubmed: 21307338
Clin Cancer Res. 2012 Apr 1;18(7):1888-900
pubmed: 22351691
Nat Immunol. 2013 Mar;14(3):298-305
pubmed: 23354484
Cancer Cell. 2013 Apr 15;23(4):435-49
pubmed: 23541952
Mol Cancer Ther. 2013 Jun;12(6):831-43
pubmed: 23729400
Transfus Med Hemother. 2013 Oct;40(5):336-43
pubmed: 24273487
Leukemia. 2014 Oct;28(10):2094-7
pubmed: 24897506
Front Oncol. 2014 May 19;4:96
pubmed: 24904820
Leukemia. 2015 Feb;29(2):474-82
pubmed: 24962017
Int J Biol Sci. 2014 Sep 13;10(9):1072-83
pubmed: 25285039
Nat Commun. 2014 Dec 15;5:5827
pubmed: 25500533
J Clin Invest. 2015 Apr;125(4):1401-18
pubmed: 25798617
Autophagy. 2015;11(7):1161-78
pubmed: 26043024
Nature. 2015 Jul 9;523(7559):183-188
pubmed: 26131937
Autophagy. 2016;12(4):713-26
pubmed: 27050463
Leukemia. 2017 Feb;31(2):292-300
pubmed: 27479180
Oncotarget. 2017 Feb 28;8(9):14604-14619
pubmed: 28099937
Blood Cancer J. 2018 Feb 13;8(2):20
pubmed: 29440639

Auteurs

Marilena Carrino (M)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Laura Quotti Tubi (L)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Anna Fregnani (A)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Sara Canovas Nunes (S)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.
Boston Children's Hospital/Harvard Medical School, Boston, MA USA.

Gregorio Barilà (G)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Livio Trentin (L)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Renato Zambello (R)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Gianpietro Semenzato (G)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Sabrina Manni (S)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Francesco Piazza (F)

1Department of Medicine, Hematology and Clinical Immunology Branch, University of Padova, Padova, Italy.
2Veneto Institute of Molecular Medicine (VIMM), Padova, Italy.

Classifications MeSH